| 33rd week of 2015 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20150224089 | COMBINATIONS OF IKKi/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS - Provided herein are methods of treating obesity and obesity-related conditions comprising the administration of combinations of IKKε/TBK1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators, and pharmaceutical compositions comprising such combinations. | 2015-08-13 |
| 20150224091 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS - Provided herein are methods for preventing and treating thrombosis in medically ill patients by administering to the patient a therapeutically effective amount of betrixaban. | 2015-08-13 |
| 20150224092 | NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE - The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising at least two drugs selected from cinacalcet, baclofen, acamprosate, mexiletine, sulfisoxazole and torasemide useful to enhance memory and related functions in healthy subjects or subjects suffering from conditions or disorders having a negative impact on their memory. | 2015-08-13 |
| 20150224093 | Kits and Methods for Treating Post Traumatic Stress Disorder (PTSD) and Hot Flashes - The present invention is directed to kits and methods for the treatment of a patient suffering from post-traumatic stress disorder (PTSD) and/or hot flashes by an administration of a mixture produced by a combination of a long acting local anesthetic combined with clonidine. The combination of the two pharmaceuticals produces a significant increase in duration and speed of onset of sympathetic blockade, increased intensity of the sympathetic blockage as well as the reduction of local anesthetic absorption locally. The combination significantly improves the efficacy, speed of onset and block intensity of a right sided cervical sympathetic ganglion injection (RCSGI) leading to increased length of resolution of PTSD and hot flashes as well as reducing the potential for complications related to absorption of the local anesthetic. | 2015-08-13 |
| 20150224094 | ADMINISTRATION OF ACETYLCHOLINESTERASE INHIBITORS TO MITIGATE NEUROTOXIN-INDUCED PARALYSIS AND RESIDUAL NEUROMUSCULAR BLOCKADE - Methods and kits for treating or reducing the likelihood of neurotoxin-induced respiratory failure in a subject, such as a victim of neurotoxic envenomation are provided. Also provided are methods for treating or reducing the likelihood of residual neuromuscular blockade in a subject to whom a nondepolarizing neuromuscular blocking agent has been administered. The methods involve administering a pharmaceutically effective dose of an acetylcholinesterase inhibitor to the subject, where the administration is not via injection. In some embodiments intra-nasal or ocular administration is used. | 2015-08-13 |
| 20150224095 | USE OF NON-PEPTIDIC NK1 RECEPTOR ANTAGONISTS FOR THE PRODUCTION OF APOPTOSIS IN TUMOR CELLS - Substance P antagonists and, in particular, non-peptidic NK1 receptor antagonists are useful for the treatment of cancer and, more specifically, human melanoma, neuroblastoma, glioma, human Hodgkin's lymphoma KM-H2, lymphoblastic leukemia, human rhabdomyosarcoma, human breast carcinoma, human Burkitt's lymphoma, human lung carcinoma, human Ewing's sarcoma, human glioma and human osteosarcoma. | 2015-08-13 |
| 20150224096 | USE AND COMPOSITION FOR TREATING DEMENTIA - There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-selective, peripheral anticholinergic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-selective, peripheral anticholinergic agent (nsPAChA) for the preparation of a pharmaceutical composition for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia and pharmaceutical compositions comprising a non-selective peripheral anticholinergic agent of formula II as illustrated in the description and an acetylcholine esterase inhibitor are also described. | 2015-08-13 |
| 20150224097 | Immediate Release Abuse Deterrent Tablet - The invention relates to an abuse deterrent immediate release tablet. | 2015-08-13 |
| 20150224098 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS - Compounds of Formula I: | 2015-08-13 |
| 20150224099 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS - The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R | 2015-08-13 |
| 20150224100 | METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION - A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years | 2015-08-13 |
| 20150224101 | Method and Compositions for Treating Cancer and Related Methods - The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib a tricyclic agent compound, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib, and wherein the tricyclic agent is administered in an amount that does not lead to a substantial central nervous system effect. In additional aspects, the invention relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy. | 2015-08-13 |
| 20150224102 | Stable pharmaceutical composition containing 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(- 4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof - The present invention relates to a stable pharmaceutical composition comprising amorphous or crystalline linagliptin or a pharmaceutically acceptable salt of linagliptin, mannitol, copovidone, and magnesium stearate, processes for preparing the stable pharmaceutical composition, and a container comprising the stable pharmaceutical composition. | 2015-08-13 |
| 20150224103 | MEK INHIBITORS IN THE TREATMENT OF VIRUS DISEASES - The present invention relates to MEK inhibitors that are capable of displaying one or more beneficial therapeutic effects. The MEK inhibitors can be used in the prevention and/or treatment of viral infection. MEK inhibitors in combination with neuraminidase inhibitor compounds are capable of displaying one or more beneficial therapeutic effects in the treatment of viral diseases. | 2015-08-13 |
| 20150224104 | METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER - Provided herein are methods of treating, preventing and/or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof. | 2015-08-13 |
| 20150224105 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES - The present invention is directed to triazolopyrimidine, phenylpyrimidine, pyridopyridazine, and pyridotriazine compounds which are microtubule-stabilizing compounds and their use in the treatment of neurodegenerative disorders, in particular, tauopathies, such as for example, Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration. In addition, the compounds of the invention may be useful for other diseases where tau pathology is a comorbidity or where microtubule function is compromised, for example, schizophrenia, Parkinson's disease (PD), PD with dementia, Lewy body disease with dementia, and amyotrophic lateral sclerosis. | 2015-08-13 |
| 20150224106 | PHARMACEUTICAL USE OF 2-(4-MORPHOLINOANILINE)-6-CYCLOHEXYL AMINOPURINE AND/OR SALT THEREOF FOR IMPROVING LIVER FUNCTIONING - A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including MMPs and TIMPs, and so it can inhibit liver fibrosis. In the liver, it can inhibit collagen synthesis and expression, and therefore reverse and treat hepatitis and liver cirrhosis effectively. Also disclosed is a method for preparing drugs for treating infective hepatitis, non-infectious hepatitis, liver injury, liver cirrhosis, liver cancer and liver fibrosis, and improving t liver functioning, in which the compound and/or salt thereof is used optionally or in combination with a target molecule or carrier comprising a vitamin A-coupled liposome. | 2015-08-13 |
| 20150224107 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2015-08-13 |
| 20150224108 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE - Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins. | 2015-08-13 |
| 20150224109 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof - The present invention provides a compound of formula I: | 2015-08-13 |
| 20150224110 | Heteroaryl-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, | 2015-08-13 |
| 20150224111 | Therapeutic Methods And Pharmaceutical Compositions For Treating Warts With Tellurium Compounds - A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments. | 2015-08-13 |
| 20150224112 | CHLOROBIS COPPER (I) COMPLEX COMPOSITIONS AND METHODS OF MANUFACTURE AND USE - A method of manufacturing an anhydrous copper complex of formula C | 2015-08-13 |
| 20150224113 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD - The present invention provides a method of treating acute heart failure by administering a compound of the formula: | 2015-08-13 |
| 20150224114 | DOSING REGIMEN OF SEDATIVE - By intravenously administering a sedative comprising methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate or a salt thereof to a patient by a dosing regimen including a two-step process disclosed in the present invention, general anesthesia can be safely and promptly induced and maintained. | 2015-08-13 |
| 20150224115 | PRESERVATIVE FREE BIMATOPROST AND TIMOLOL SOLUTIONS - The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma. | 2015-08-13 |
| 20150224116 | Combination of Azelastine and Fluticasone for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 2015-08-13 |
| 20150224117 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 2015-08-13 |
| 20150224118 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 2015-08-13 |
| 20150224119 | Implants and methods for treating inflammation-mediated conditions of the eye - Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks. | 2015-08-13 |
| 20150224120 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLINEMIA-ASSOCIATED MENTAL DISORDERS - The present invention provides methods for treating or ameliorating the effects of schizophrenia, which include administering to a patient in need thereof a therapeutically effective amount of a proline modulator. Further provided are methods of selecting a patient at risk for or suffering from schizophrenia that is likely to benefit from proline modulation. Methods for identifying an agent that modulates proline levels in a patient and methods for identifying a patient at risk for developing a DTNBP1-related psychiatric illness, as well as other methods and compositions for treating or ameliorating the effects of schizophrenia are also provided. | 2015-08-13 |
| 20150224121 | PARENTERAL COMPOSITIONS OF CELECOXIB - Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less. | 2015-08-13 |
| 20150224122 | THERAPEUTIC USES OF GLUTATHIONE MIMICS - A prodrug having antioxidant activity, including a phosphorylated compound having a thiol group. A method of treating oxidative stress by administering a prodrug of a phosphorylated compound including a thiol group, removing a phosphate group of the prodrug, and treating oxidative stress. A method of increasing bioavailability of a thiol compound by creating a prodrug by phosphorylating a thiol compound, administering the prodrug, preventing first pass metabolism of the prodrug, removing a phosphate group from the prodrug, and providing active drug to a site in need of therapy from oxidative stress. A method of preventing radiation damage to healthy tissue by administering a prodrug comprising a phosphorylated compound including a thiol group, removing a phosphate group of the prodrug to provide active drug, and preventing radiation damage to healthy tissue. | 2015-08-13 |
| 20150224123 | THERAPEUTIC USES OF GLUTATHIONE MIMICS - A prodrug having antioxidant activity, including a phosphorylated compound having a thiol group. A method of treating oxidative stress by administering a prodrug of a phosphorylated compound including a thiol group, removing a phosphate group of the prodrug, and treating oxidative stress. A method of increasing bioavailability of a thiol compound by creating a prodrug by phosphorylating a thiol compound, administering the prodrug, preventing first pass metabolism of the prodrug, removing a phosphate group from the prodrug, and providing active drug to a site in need of therapy from oxidative stress. A method of preventing radiation damage to healthy tissue by administering a prodrug comprising a phosphorylated compound including a thiol group, removing a phosphate group of the prodrug to provide active drug, and preventing radiation damage to healthy tissue. | 2015-08-13 |
| 20150224124 | REDUCING THE REPRODUCTIVE CAPACITY OF MAMMALS - Provided are compositions and methods for reducing the reproductive capacity of mammals. The compositions and methods involve the use and administration of (a) a diterpenoid epoxide comprising a triptolide skeleton and which causes ovarian follicle depletion in female mammals and (b) an organic diepoxide which causes ovarian follicle depletion in female mammals. | 2015-08-13 |
| 20150224125 | BETA-LACTAMASE INHIBITORS - Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections. | 2015-08-13 |
| 20150224126 | COMPOSITIONS AND METHODS FOR TISSUE REGENERATION - Methods and compositions using an orthosilicate for tissue regeneration, such as to treat a disease or condition, are described, including on the skin. Also described are methods for making such compositions. | 2015-08-13 |
| 20150224127 | COLON CLEANSING OF RESIDUAL STOOL AND SECRETIONS DURING COLONOSCOPY - This invention relates, e.g., to a composition comprising two or more of: (a) N-acetylcysteine and/or (b) simethicone and/or (c) a docusate salt. In one embodiment of the invention, the amounts of (a) and/or (b) and/or (c) are effective, when the composition is administered into a colon of a subject undergoing colonoscopy, to cleanse a region of the colon in the visual field of the colonoscope so that the region contains no adherent stool or intestinal secretions obscuring the visual field. Methods for using this or other compositions of the invention, e.g. to cleanse the colon of a subject in order to enhance visualization of the colon during a colonoscopy, are also described, as are kits for carrying out methods of the invention. | 2015-08-13 |
| 20150224128 | IMINOSUGARS AND METHODS OF TREATING VIRAL DISEASES - Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars. | 2015-08-13 |
| 20150224129 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PROPHYLACTIC TREATMENT OF BACTERIAL SUPERINFECTIONS POST-INFLUENZA WITH INVARIANT NKT CELL AGONISTS - The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with iNKT cell agonists. | 2015-08-13 |
| 20150224130 | Solid Carriers for Improved Delivery of Active Ingredients in Pharmaceutical Compositions - The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents. | 2015-08-13 |
| 20150224131 | siRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions - The invention relates to methods and compositions for the treatment and/or prevention of eye conditions related to high levels of expression and/or activity of the vanilloid-1 receptor (TRPV). | 2015-08-13 |
| 20150224132 | COMPOSITIONS AND METHODS FOR TREATING FIBROTIC DISEASE - The present disclosure relates to compositions and methods for treating or preventing a fibrotic disorder or disease. | 2015-08-13 |
| 20150224133 | RESORBABLE OXIDIZED CELLULOSE EMBOLIZATION SOLUTION - A method for forming an embolism within a blood vessel is disclosed. The method includes including: implanting an oxidized cellulose embolization solution into a lumen of a blood vessel to form an embolism within the lumen. The oxidized cellulose is present in an amount from about 10% by weight to 20% by weight of the oxidized cellulose embolization solution. The method also includes adjusting recanalization time of the embolism, which may be adjusted by tailoring a degradation rate of the oxidized cellulose. | 2015-08-13 |
| 20150224134 | NANO-TARGETED DELIVERY OF PROTEASE, POLYMERASE INHIBITORS WITH OR WITHOUT IMMUNE MODULATORS IN THE TREATMENT OF HEPATITIS C - This disclosure concerns novel formulation and Nanoformulations as defined in the specification and compositions comprising combination of HCV protease and polymerase inhibitors, with or without interferon, along with anti-fibrotic/anti-hemolytic agents' combination of naturally driven Polyphenol/Thiols, and Non-anticoagulant GAGs. These compounds are effective antiviral agents, especially in inhibiting the function of the various genotypes of Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising nano-targeted delivery of novel nanoformulation containing combined composition for HCV and/or hepatic targeted delivery for improved efficacy and safety. | 2015-08-13 |
| 20150224135 | BIOCIDAL POLYMERS - Pharmaceutical compositions containing biocidal co-polymers of poly(styrenes), poly(acrylates), poly(acrylamides), and poly(C | 2015-08-13 |
| 20150224136 | Performance-Enhancing Nasal Irrigation - Novel compositions for performance-enhancing nasal irrigation, nasal irrigation apparatus for delivering said performance-enhancing compositions, and methods for enhancing performance using said compositions. Any combination of salt, baking soda, one or more alkaline earth metals, one or more amino acids, one or more natural antioxidants, one or more plant-based stimulants, one or more vitamins, and one or more synergists or other ingredients are disclosed. The ingredients described herein may be delivered as an anhydrous powder packet containing water-soluble forms of the component ingredients, and may be delivered along with nasal irrigation devices and instructions for mixing the powder with a fixed volume of pure water. | 2015-08-13 |
| 20150224137 | CITRATE-RICH CALCIUM-MAGNESIUM SUPPLEMENT AND USES THEREOF - Disclosed is an effervescent preparation of calcium and magnesium with additional citric acid in a defined ratio. Also disclosed is the use of these compositions to raise cardioprotective citrate and magnesium in serum to help prevent heart attacks from calcium supplements, and to provide bioavailable calcium and magnesium to prevent osteoporosis-related fractures and low blood magnesium from the use of proton pump inhibitors. | 2015-08-13 |
| 20150224138 | Use of Electrolyzed Water for Treatment and Prevention of Common Livestock Diseases and Conditions, Including PRRS - Respiratory symptoms resulting from disease states such as PRRS and | 2015-08-13 |
| 20150224139 | STABILIZED CHLORINE DIOXIDE TO PRESERVE CARBOHYDRATE FEEDSTOCKS - A process to preserve a carbohydrate feedstock against contaminant microorganisms comprises contacting the carbohydrate feedstock with a stabilized chlorine dioxide at a pH of at least 2.6. The carbohydrate feedstock preferably comprises a naturally-occurring carbohydrate, particularly a carbohydrate having a reducing end group. The process is particularly suitable to treat feedstocks used in biorefining processes, such as in ethanol fermentation. | 2015-08-13 |
| 20150224140 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS - The embodiments disclosed herein relate to compositions for enhancing brain glucose transporters, such as GLUT1 and GLUT3, and methods of treating and/or preventing diseases or disorders associated with the regulation GLUT1 and GLUT3. Also provided are compositions that include chromium and an agent that targets the brain or the central nervous system. Further provided are improved methods of delivering therapeutic agents that target the brain and/or central nervous system. | 2015-08-13 |
| 20150224141 | METHODS OF USING SMALL COMPOUNDS TO ENHANCE MYELOID DERIVED SUPPRESSOR CELL FUNCTION FOR TREATING AUTOIMMUNE DISEASES - Methods for enhancing the suppressive function of myeloid derived suppressor cells (MDSCs) for the treatment of autoimmune diseases using small compounds are disclosed. In certain aspects, the small compounds are glatiramer acetate and mitogen activated protein (MAP) kinase inhibitors. In other aspects, these methods include the administration of exogenous MDSCs or the use of endogenous MDSCs mobilized using stem cell mobilizers. In yet other aspects, compositions containing MDSCs and small compounds of the invention are provided. | 2015-08-13 |
| 20150224142 | INHIBITION OF DIACYLGLYCEROL KINASE TO AUGMENT ADOPTIVE T CELL TRANSFER - The present invention provides compositions and methods for inhibiting one or more diacylglycerol kinase (DGK) isoform in a cell in order to enhance the cytolytic activity of the cell. In one embodiment, the cells may be used in adoptive T cell transfer. For example, in some embodiments, the cell is modified to express a chimeric antigen receptor (CAR). Inhibition of DGK in T cells used in adoptive T cell transfer increases cytolytic activity of the T cells and thus may be used in the treatment of a variety of conditions, including cancer, infection, and immune disorders. | 2015-08-13 |
| 20150224143 | SELECTIVE AND CONTROLLED EXPANSION OF EDUCATED NK CELLS - The present invention relates generally to immunotherapy. Disclosed herein are methods for obtaining cytolytic differentiated NKG2A | 2015-08-13 |
| 20150224144 | ANTI-COMPLEMENT THERAPY COMPOSITIONS AND METHODS FOR PRESERVING STORED BLOOD - Provided herein is a composition comprising transfusable red blood cells having improved storage capability, wherein a C9 inhibitor has been administered to the composition and thereby the composition has a reduced amount of red blood cell lysis as compared to a control. It is a surprising finding of the present invention that addition of a C9 inhibitor to a blood sample decreases the amount of red cell lysis in the sample over time. Accordingly, the present invention provides red blood cell compositions that can be stored for greater lengths of time before use, i.e., transfusion, and/or that have a reduced amount of storage lesion. | 2015-08-13 |
| 20150224145 | METHOD OF WASHING ADHERENT CELL USING TREHALOSE-CONTAINING CELL-WASHING SOLUTION - Methods of washing adherent cells, capable of effectively suppressing cell death due to proteolytic enzyme treatment for detaching the adherent cell from a culture vessel and subsequent cell treatment; cell-washing solutions used for the washing method; methods of producing cell suspensions for transplantation using the cell-washing solution; and kits comprising the cell-washing solution. Trehalose or its derivative or a salt thereof is added to physiological aqueous solutions to prepare cell-washing solutions containing trehalose or its derivative or a salt thereof as an active ingredient. The cell-washing solutions can be used to wash adherent cells before detaching the adherent cells from a culture vessel by proteolytic enzyme treatment to suppress cell death due to the proteolytic enzyme treatment. The concentration of trehalose applied to the cell-washing solution may be a concentration capable of suppressing the cell death due to the proteolytic enzyme treatment, such as 0.1 to 20 (w/v) %. | 2015-08-13 |
| 20150224146 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES - The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues. | 2015-08-13 |
| 20150224147 | Placental Membrane Preparation and Methods of Making and Using Same - This disclosure relates to placental membrane preparations and the methods of preparing and using thereof. In some embodiments, the disclosure relates to a placental membrane preparation. In some embodiments, the disclosure relates to methods of producing a placental membrane preparation. In some embodiments, the disclosure relates to methods of treating cartilage using placental membrane preparations. | 2015-08-13 |
| 20150224148 | TREATMENT OF PAIN USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™). | 2015-08-13 |
| 20150224149 | COMPOSITION FOR PARENTERAL ADMINISTRATION, METHOD FOR PRODUCING AND METHOD USE THEREOF - The present invention relates to a field of veterinary and human medicine. In particular, the invention relates to a composition suitable for parenteral administration, based on hydrolyzate obtained from natural bioresources, a composition for use in treating and/or preventing a pathological condition in a mammal in need thereof, and various other uses thereof. More particularly the invention relates to a composition having immunomodulatory properties being based on a hydrolyzate obtained from bioresources, which composition is used for parenteral administration to a mammal in need thereof. | 2015-08-13 |
| 20150224150 | PREPARATION AND METHOD FOR THE PROPHYLAXIS AND TREATMENT OF ATYPICAL OSTEOPOROSIS - The method and preparation for preventing and treating atypical osteoporosis with normal or increased bone tissue mineralization with the presence of cavities in trabecular bone sections (and conditions similar thereto involving excess mass and metabolic syndrome) relate to medicine, in particular to agents for the treatment and prevention of conditions associated with various forms of osteoporosis, particularly involving metabolic syndrome. The method is characterised in that it involves taking between 10 mg and 1000 mg per day of drone brood and between 50 IU and 100,000 IU per day of vitamin D or vitamins of this group and/or the active metabolites thereof so as to be supplied to the body at the same time daily; and the preparation is composed of between 10 mg and 1000 mg per day of drone brood and between 50 IU and 100,000 IU per day of vitamin D or vitamins of this group and/or the active metabolites thereof can be provided in powder, tablet or capsule form. Implementing the invention provides for the achievement of the technical result stated by the author of creating an agent that facilitates the redistribution of calcium in the body: the reduction of mineralization in soft tissues, vessels and other organs, as well as filling cavities in trabecular bone. | 2015-08-13 |
| 20150224151 | USE OF MYCOBACTERIUM BRUMAE TO TREAT BLADDER CANCER | 2015-08-13 |
| 20150224152 | METHODS FOR MODULATING BACTERIAL INFECTION - The present invention relates to methods for treating or reducing the risk of or preventing diseases caused by or associated with pathogenic bacteria. More particularly, the present invention relates to methods for treating or reducing the risk of or preventing diseases caused by or associated with pathogenic bacteria of the gastrointestinal (GI) tract. The present invention further relates to methods for promoting pathways induced by commensal bacteria of the GI tract that lead to Th17 differentiation, which in turn leads to localized and systemic accumulation of Th17 cells. Compositions and medicaments are also described herein that are used alleviate and/or prevent symptoms associated with diseases caused by or associated with pathogenic bacteria. Accordingly, the compositions, medicaments and methods described herein may be used to address the needs of patients or subjects that would benefit from increased Th17 cell differentiation. | 2015-08-13 |
| 20150224153 | PROBIOTICS FOR USE IN REDUCING EOSINOPHILIA AND RESPIRATORY ALLERGIES - The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms. | 2015-08-13 |
| 20150224154 | Low/High Dose Probiotic Supplements And Methods Of Their Use - Methods and compositions are hereby disclosed for reducing the numbers of | 2015-08-13 |
| 20150224155 | LIQUID VIRAL FORMULATIONS - Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage. | 2015-08-13 |
| 20150224156 | PAECILOMYCES VARIOTII VAR. BRUNNEOLUS GPP1101B, AND PREPARATION USING SAME - The present invention relates to a | 2015-08-13 |
| 20150224157 | PROCESS FOR THE PREPARATION OF HERBAL EXTRACT OF CASSIA TORA LEAVES FOR TREATING ANXIETY DISORDERS - The present invention relates to novel use of the extracts of | 2015-08-13 |
| 20150224158 | FERMENTED PLANT EXTRACTS, METHODS OF PRODUCTION AND USES - The present disclosure concerns plant extracts which have been fermented with kefir grains, methods of production of these extracts, a powder comprising these extracts and compositions comprising these extracts. Since these extracts have a high content of aglycone active principles, their biological activities are high and their applications are varied. | 2015-08-13 |
| 20150224159 | EXTRACTS OF PERILLA FRUTESCENS SEEDS AND THEIR PHARMACEUTICAL USES - Disclosed is an extract of | 2015-08-13 |
| 20150224160 | PLANT EXTRACT, COMPOSITIONS CONTAINING SAME, METHOD OF EXTRACTION AND USES THEREOF - An extract from leaves of mulberry is disclosed. The extract has an IC | 2015-08-13 |
| 20150224161 | METHODS AND USES OF AN EXTRACT FROM OLIVE LEAF IN MANAGEMENT OF TYPE 2 DIABETES - Described herein are methods and uses of oleuropein and hydroxytyrosol in a variety of applications to prevent, reduce symptoms of and treat conditions related to insulin sensitivity including type 2 diabetes. | 2015-08-13 |
| 20150224162 | COMPOSITION FOR USE IN THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - The invention provides a composition the prevention and treatment of cardiovascular disease, wherein said composition compounds obtained from palm oil mill effluents, in particular from vegetative liquor from the milling of palm oil fruit. | 2015-08-13 |
| 20150224163 | TREATMENT OF NOISE INDUCED HEARING LOSS - The present invention provides methods of preventing, treating, and/or reducing noise induced hearing loss and/or noise-induced inner ear trauma. The methods include the administration of glatiramer acetate or a derivative thereof and, optionally, at least one anti-oxidant. | 2015-08-13 |
| 20150224164 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACID - This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders. | 2015-08-13 |
| 20150224165 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIA - The presently-disclosed subject matter provides methods for preventing ischemia in a cell, treating ischemia in a subject, and preventing an infarction in a subject that utilize α5β1 integrin inhibitor. In some instances, α5β1 integrin inhibitor is administered to a subject prior to, during, or after the onset of ischemia to treat the ischemia and/or prevent infarction. In some instances the present methods prevent the occurrence of an infarction. In some instances the present methods restores perfusion to organs and tissues. | 2015-08-13 |
| 20150224166 | Sincalide Formulations - The invention features sincalide formulations that include an effective amount of sincalide, a bulking agent/tonicity adjuster, a stabilizer, a surfactant, a chelator, and a buffer. The invention also features kits and methods for preparing improved sincalide formulations as well as methods for treating, preventing, and diagnosing gall bladder-related disorders using sincalide formulations. | 2015-08-13 |
| 20150224167 | COMPOSITION FOR PROMOTING WOUND HEALING - The present disclosure relates to a composition for promoting wound healing that may be used as a pharmaceutical composition, or a cosmetic composition for promoting wound healing, which contains a polypeptide including an amino acid sequence of SEQ ID NO 1. The composition may be usefully used for a wound care drug or a functional cosmetic product for wound care. | 2015-08-13 |
| 20150224168 | COMBINATIONS WITH A BACKBONE-CYCLIZED PEPTIDE - A novel combination comprising a β-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn- | 2015-08-13 |
| 20150224169 | COMPOUNDS AND METHODS FOR SELECTIVELY TARGETING CANCER STEM CELLS - Described are compounds and methods useful for selectively targeting cancer stem cells. The compounds preferentially induce differentiation and/or reduce the proliferation of cancer stem cells relative to normal stem cells. Compounds useful for selectively targeting cancer stem cells include polyene macrolides such as Nystatin or Amphotericin B, analogs thereof and pharmaceutically acceptable salts thereof. | 2015-08-13 |
| 20150224170 | Methods of Inhibiting Alphavirus Replication and Treating Alphavirus Infection - The invention provides methods of inhibiting alphavirus replication and treating alphavirus infection. | 2015-08-13 |
| 20150224171 | COMPOSITION WITH INCREASED BIOAVAILABILITY OF ORALLY ADMINISTERED EMBRYO-PEPTIDES AND PROCESS FOR ITS OBTAINMENT - The invention refers to a composition standardized in heterologous embryo-peptides, used as a dietary supplement and to a process for its obtainment. The composition consists of heterologous embryonic extract, standardized in embryo-peptides, maltodextrin, selenium yeast, chromium yeast, zinc chelated in embryo-peptides, pyridoxine, mixture of cationic peptides, formed by enzymatic hydrolysis of vitellus and egg white remaining after chicken embryo harvesting, with antitrypsin and endocytosis promoting activity, sodium taurocholate, expanded silicon dioxide, magnesium stearate, methylparaben and propylparaben. The process of obtainment consists of the following steps: obtaining and disintegration of biological material, diluting with sterile water, homogenization and dissociation of embryonic growth factors from their soluble receptors; embryo-peptides concentration through tangential ultrafiltration; embryo-protein denaturation and mixing of embryo-peptides with denatured proteins; obtainment of cationic peptides and their addition and of others components over the mixture embryo peptides-embryo proteins, homogenization and spray-drying of the final mixture. | 2015-08-13 |
| 20150224172 | USE OF KGF IN THE TREATMENT OF MENOPAUSAL DISORDERS - The present invention relates to the use of keratinocyte growth factor (KGF/FGF7) and pharmaceutical compositions thereof in the treatment of vaginal atrophy, dysuria, vaginal pain and/or vaginal dryness induced by a post-menopausal state, by surgical intervention, by illness and/or by chemotherapy or radiotherapy treatments. | 2015-08-13 |
| 20150224173 | METHOD OF PREPARING A GROWTH FACTOR CONCENTRATE DERIVED FROM HUMAN PLATELETS - The invention relates to a method of preparing an intra-dermally, intra-articularly, sub-dermally or topically administrable growth factor concentrate derived from human platelets. The method comprises the steps of suspending human platelets in multiple electrolyte isotonic solution; snap-freezing the suspension; thawing the frozen suspension; and sterile-filtering the suspension. In particular, in this method, a fixed number of platelets is suspended in a fixed volume of multiple electrolyte isotonic solution to obtain the required concentration of growth factors in the growth factor concentrate, snap-freezing of the suspension is carried out at a temperature of −120° C. to −200° C., thawing of the frozen suspension is carried out at 25° C. to 37° C., and cellular debris are separated from the thawed suspension and the resultant suspension of growth factors is diluted with an isotonic medium before sterile-filtering. | 2015-08-13 |
| 20150224174 | Use of Natriuretic Peptide for Treating Heart Failure - The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours. | 2015-08-13 |
| 20150224175 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING RECOVERY OF PERIPHERAL NEUROPATHY - Without limitation, some embodiments comprise a method of treatment for promoting recovery of peripheral neuropathy in a subject, including administering to a subject in need of such treatment a therapeutically effective amount of a composition comprised of thymosin beta 4, amino acid sequences LKKTET or LKKTNT, and/or any conservative variants thereof, or an agent that stimulates production of any of those materials, or a conservative variant thereof. | 2015-08-13 |
| 20150224176 | Pharmaceutical microparticulate compositions of polypeptides - The present invention refers to pharmaceutical microparticulate compositions of biologically active polypeptides and methods of forming and using such compositions. More particularly, microparticle compositions for sustained release of biologically active polypeptides are provided. Compositions of biologically active polypeptides with desired release profile can be prepared without using any sugar. The microparticle compositions of this invention comprise a biocompatible polymer, a biologically active polypeptide, and optionally, pharmaceutical excipients other than sugar. | 2015-08-13 |
| 20150224177 | METHODS FOR THERAPEUTIC OR PROPHYLACTIC TREATMENT OF MELIOIDOSIS AND/OR ASSOCIATED DISEASES - The present invention generally relates to a method for therapeutic or prophylactic treatment of melioidosis and/or associated diseases in a subject in need thereof, comprising administering to said subject an effective amount of a pharmaceutical composition comprising either one ion selected from the group of the hypothiocyanites (OSCN | 2015-08-13 |
| 20150224178 | NOVEL POWDERED MILK PRODUCT AND METHOD FOR PRODUCING THE SAME - The invention relates to a powdered milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 1.4 to 24 mg/15 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.35 to 10. | 2015-08-13 |
| 20150224179 | COMPOSITION CAPABLE OF IMPROVING STABILITY OF BACTERIOPHAGE LYSIN PROTEINS - The present invention relates to a composition for improving the stability of bacteriophage originated lysin proteins greatly even when the composition contains the bacteriophage originated lysin proteins at a high concentration. More precisely, the present invention relates to a method and a composition for improving significantly the stability of SAL-1 or LysK, the bacteriophage originated lysin protein, included at a high concentration in the composition. | 2015-08-13 |
| 20150224180 | PURIFICATION AND ISOLATION OF RECOMBINANT OXALATE DEGRADING ENZYMES AND SPRAY-DRIED PARTICLES CONTAINING OXALATE DEGRADING ENZYMES - The present invention comprises methods and compositions for the reduction of oxalate in humans, and methods for the purification and isolation of recombinant oxalate reducing enzyme proteins. The invention provides methods and compositions for the delivery of oxalate-reducing enzymes in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions. | 2015-08-13 |
| 20150224181 | BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE - protein can be used to induce | 2015-08-13 |
| 20150224182 | TARGET PEPTIDES FOR IMMUNOTHERAPY AND DIAGNOSTICS - A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex. | 2015-08-13 |
| 20150224183 | BACTERIAL RIBONUCLEIC ACID CELL WALL COMPOSITIONS AND METHODS OF MAKING AND USING THEM - The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity. | 2015-08-13 |
| 20150224184 | ENGINEERED ANTHRAX LETHAL TOXIN FOR TARGETED DELIVERY - The present invention provides methods and systems for targeted delivery of a compound to a target cell that overexpresses two different proteinases. Specifically, two different modified protective antigen proteins, each comprising a cleavage site recognized by a distinct proteinase in place of the native proteinase cleavage site recognized by furin, are administered in combination with a compound that contains a protective antigen binding site. Upon cleavage by the two proteinases the two modified protective antigen proteins form a hetero-oligomer, allowing the compound to bind to the hetero-oligomer and subsequently to be translocated into the target cell. | 2015-08-13 |
| 20150224185 | IMMUNOGENIC COMPOSITIONS - The invention provides an immunogenic composition comprising one or more GBS conjugates and one or more antigens selected from: a) cellular or acellular pertussis antigen, b) a tetanus toxoid, c) a diphtheria toxoid and d) an inactivated polio virus antigen, wherein each GBS conjugate is a group B | 2015-08-13 |
| 20150224186 | HPV E6 PROTEIN T CELL EPITOPES AND USES THEREOF - The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual. | 2015-08-13 |
| 20150224187 | ATTENUATED INFLUENZA VACCINES AND USES THEREOF - Provided herein are attenuated influenza viruses and methods of making attenuated influenza viruses. | 2015-08-13 |
| 20150224188 | USE OF MEMBRANE VESICLE-BASED VACCINE AGAINST M. TUBERCULOSIS - Provided are compositions comprising a plurality of isolated | 2015-08-13 |
| 20150224189 | SILICON DIOXIDE NANOPARTICLES AND THE USE THEREOF FOR VACCINATION - The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal. | 2015-08-13 |
